LegoChem Biosciences is brought into the limelight with multiple instances of bold strides made within the biotech industry. Most notably, LegoChem pulls in an impressive
$411M from Orion, a Korean confectionery company, leading to Orion's acquisition of a
majority stake in LegoChem at $415 million. This strategic investment assists LegoChem in research and advancements within targeted cancer drug development. High value licensing and partnership agreements have been highlighted such as the
$1.7bn licensing deal with Janssen, part of
J&J company, and collaborations with
Samsung Biologics focusing on antibody-drug conjugates (ADC) therapy. Furthermore, LegoChem's bold steps are resonated by their partnerships with significant biotech actors such as
Amgen, NextCure, Antegene, and Glycotope among others, amping up ADC treatment development. Despite being currently unprofitable, LegoChem has managed a
92% return to shareholders over 5 years. Notable mentions include potential name changes due to legal conflicts with popular toy company, Lego, and FDA approval for phase 1,2 trials of LCB84.
Legochem News Analytics from Mon, 13 Feb 2017 08:00:00 GMT to Wed, 08 May 2024 23:29:46 GMT -
Rating 9
- Innovation 7
- Information 8
- Rumor 2
